Purpose: Targeted cancer therapy (TCT) is a significant advancement in oncology with promising survival improvement in patients with cancer and remarkable effects on various cancers. There is evidence suggesting a connection between specific TCT classes and the occurrence of immune-related adverse events (irAEs). Our study aims to investigate the potential ocular toxicities of different classes of TCT, provide a better understanding of these toxicities, and aid in the future development of screening and management recommendations for ocular irAEs. Design: Retrospective observational case series. Participants: Only ocular immune-related AEs were included in the study; patients on TCT who received a new ophthalmic diagnosis were seen at the MD Anderson Cancer Center. Methods: Between 2010 and 2019, we retrospectively reviewed the medical records of 6,354 patients on TCT at a large US tertiary cancer center. Results: The criteria for data analysis were met by 1861 patients. TCT was associated with a wide range of class-specific ocular irAEs. There was a statistically significant correlation between ocular toxicity with polytherapy with a p-value of <0.001. Furthermore, there was a statistically significant correlation between toxicity and BRAF, epidermal growth factor receptor (EGFR), and ICI <0.001, <0.001, and 0.006, respectively. Conclusion: Our cohort is the most extensive case series in English literature, demonstrating the increased risk of class-specific ocular toxicity associated with TCT, which sheds some light on the importance of developing standardized grading criteria and management guidelines.
Background: This report aims to observe a clinical association between obesity, and COVID-19 symptoms and post infection symptoms. Along with the importance of supportive treatment, in detection of COVID-19 complications, as early detection and intervention made a huge difference in patients’ prognosis. Subjects and Methods: After verbal consent and clearance from ethics committee, all the 3 patients (n=3) presenting with common cold, fever, cough, and breathlessness, along with obesity were considered for entry to this study. The diagnosis of COVID-19 was confirmed via a positive rtPCR test among all the patients. All the patients were given standard treatment. Results: All the 3 cases were obese adults aged 51 years old male, 33-year-old male, and 45- year-old female, all of them presented with fever, cough, breathlessness, and body ache simulating a respiratory tract viral infection. They were initially treated with Cephalosporin IV 1 g, Levaquin 750 mg daily, and subcutaneous injection of low molecular weight heparin 40 mg BID, Dexamethasone 6 mg IV BID depending upon the clinical status of these patients. Those patients who had lower oxygen saturation below 90% (n=2) were also administered dexamethasone dosage to 8 mg BID IV, and meropenem to 1 g IV BID, and continue supportive treatment for possible benefit. All patients recovered. Conclusions: Over the course of our 3 cases series, we were able to observe a clinical association between obesity, and COVID-19 symptoms, and post-infection symptoms. While this is a preliminary outcome on the impact, it does raise questions about disease modifications in patients with obesity, and its impact on response to treatment. We also saw the importance of supportive treatment, in the detection of COVID-19 complications, as early detection and intervention made a huge difference in patients’ prognosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.